These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7461013)

  • 1. Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease.
    Meinertz T; Kersting F; Kasper W; Just H; Bechtold H; Jähnchen E
    Eur J Clin Pharmacol; 1980 Nov; 18(6):461-5. PubMed ID: 7461013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic effects of encainide, flecainide, lorcainide and tocainide.
    Vanhaleweyk G; Serruys PW; Hugenholtz PG
    Eur Heart J; 1984 Sep; 5 Suppl B():67-74. PubMed ID: 6437819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic implications of lorcainide therapy in patients with normal and depressed cardiac function.
    Somani P; Fraker TD; Temesy-Armos PN
    J Clin Pharmacol; 1987 Feb; 27(2):122-32. PubMed ID: 3680563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamic reactions after intravenous injection of lorcainide hydrochloride in acute myocardial infarction.
    Shita A; Bernard R; Mostinckx R; Debacker M
    Eur J Cardiol; 1981; 12(5):237-42. PubMed ID: 7250167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease.
    Legrand V; Vandormael M; Collignon P; Kulbertus HE
    Am J Cardiol; 1983 Feb; 51(3):422-6. PubMed ID: 6823856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular profile of 5 novel nitrate-esters: a comparative study with nitroglycerin in pigs with and without left ventricular dysfunction.
    van Woerkens LJ; van der Giessen WJ; Verdouw PD
    Br J Pharmacol; 1991 Sep; 104(1):7-14. PubMed ID: 1786521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorcainide (R 15 889), a first review.
    Amery WK; Heykants JJ; Xhonneux R; Towse G; Oettel P; Gough DA; Janssen PA
    Acta Cardiol; 1981; 36(3):207-34. PubMed ID: 7020313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological effects of a new antiarrhythmic agent, lorcainide, on the isolated cardiac muscle fiber as compared with disopyramide.
    Shigenobu K; Atoda H; Asano T; Kasuya Y
    J Pharmacobiodyn; 1980 Dec; 3(12):677-85. PubMed ID: 7277183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.
    Pagel PS; Harkin CP; Hettrick DA; Warltier DC
    Anesthesiology; 1994 Oct; 81(4):974-87. PubMed ID: 7943849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Electrophysiologic effects of lorcainide (R 15889) in man].
    Touboul P; Atallah G; Kirkorian G
    Arch Mal Coeur Vaiss; 1981 Nov; 74(11):1333-40. PubMed ID: 6797372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiological actions of lorcainide in patients with cardiac disease.
    Kasper W; Meinertz T; Kersting F; Löllgen H; Lang K; Just H
    J Cardiovasc Pharmacol; 1979; 1(3):343-52. PubMed ID: 94401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerance of intravenous lorcainide in patients with normal and impaired intraventricular conduction.
    Stroobandt R; Kesteloot H
    Acta Cardiol; 1985; 40(6):637-48. PubMed ID: 3879420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemodynamic effects of the antiarrhythmic quaternary ammonium compound QX-572 in man.
    Rydén L; Hjalmarson A ; Kvasnicka J; Liander B
    Br Heart J; 1975 Jan; 37(1):65-73. PubMed ID: 1089426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
    Echt DS; Mitchell LB; Kates RE; Winkle RA
    Circulation; 1983 Aug; 68(2):392-9. PubMed ID: 6861314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative electrophysiology of lorcainide and norlorcainide in the dog.
    Keefe DL; Kates RE; Winkle RA
    J Cardiovasc Pharmacol; 1984; 6(5):808-15. PubMed ID: 6209484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.
    Somani P; Temesy-Armos PN; Leighton RF; Goodenday LS; Fraker TD
    Am Heart J; 1984 Dec; 108(6):1443-8. PubMed ID: 6507240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison in vitro of the electrophysiological effects of lorcainide and its metabolite norlorcainide.
    Carmeliet E
    Eur J Pharmacol; 1987 Jan; 133(1):29-36. PubMed ID: 3556390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic effect of lorcainide in patients taking digoxin.
    Giardina EG; Raby K; Saroff AL; Louie-Chu M
    J Clin Pharmacol; 1987; 27(5):378-83. PubMed ID: 3693581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological characteristics of lorcainide, a new antiarrhythmic drug.
    Solti F; Czakó E; Szatmáry L
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):26-9. PubMed ID: 3957486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological effects of lorcainide, a new antiarrhythmic drug. Observations in patients with and without pre-excitation.
    Bär FW; Farré J; Ross D; Vanagt EJ; Gorgels AP; Wellens HJ
    Br Heart J; 1981 Mar; 45(3):292-8. PubMed ID: 7470342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.